Treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone lymphoma, motion sickness, ...
The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.
Investing.com -- Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 8% after the U.S. Food and Drug Administration (FDA) approved the company’s Linzess (linaclotide) capsules for pediatric patients 7 ...
The FDA announced that it will relax certain rules for approving low-cost versions of some high-priced medications.
Lifileucel shows a 25.6% objective response rate and 71.8% disease control rate in advanced nonsquamous NSCLC patients, ...
The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...
The Food and Drug Administration awarded the drug’s sponsor, biotech company Revolution Medicines, a new and unconventional ...
The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as ...
Q3 2025 Earnings Call Transcript November 4, 2025 Taysha Gene Therapies, Inc. misses on earnings expectations. Reported EPS ...
Is Galleri the future of cancer treatment? It's not that simple. The new research from the company, while promising, isn't ...
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan ...
Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback